A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Associate Medical Director - Global Safety Medical Review

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote in USARemote

About the Job

Requirements

  • An MD degree and at least 1 year of clinical medical practice are required.
  • At least 3 years of pharmaceutical industry experience in medical review or a related pharmacovigilance role are required.
  • Strong clinical acumen and broad knowledge and experience across multiple therapeutic areas are required.
  • The role requires synthesizing, critically evaluating, and interpreting safety data from individual case safety reports, aggregate safety data, and other relevant sources.
  • The role requires analytical, critical-thinking, and problem-solving skills to assess complex medical and safety issues and identify matters requiring further investigation or escalation.
  • Strong written and verbal communication skills are required to communicate medical and safety findings to cross-functional stakeholders.
  • A strong understanding of international pharmacovigilance regulations and drug safety requirements is required.
  • The role requires managing multiple priorities and meeting rapidly approaching timelines in a fast-paced, complex, collaborative environment.
  • The role requires collaboration with cross-functional teams, case processing teams, medical review vendors, and other pharmacovigilance stakeholders to ensure high-quality, consistent, timely safety assessments.

Responsibilities

  • Perform daily medical review and causality assessment of individual case safety reports accurately, consistently, and in a timely manner to support continuous signal detection and management.
  • Support and participate in medical device safety assessments, including evaluating MDR-related cases and determining whether reported events meet applicable criteria for public health threats, regulatory reporting, escalation, or further medical assessment.
  • Collaborate with pharmacovigilance colleagues to align a harmonized approach to identifying, evaluating, and communicating safety issues.
  • Identify topics for escalation and collaborate with Safety Product Leads to investigate potential safety signals.
  • Review safety data and aggregate datasets to identify emerging trends, patterns, inconsistencies, and potential safety signals.
  • Provide medical and clinical input into data review plans, surveillance activities, and safety monitoring strategies to ensure appropriate, consistent medical assessment of safety information.
  • Collaborate with SRM Quality and Case Management teams to identify case review issues and inconsistencies and address them under the leadership of the Head of Medical Review.
  • Participate in process improvements for the Medical Review team.
  • Maintain close communication with case processing and medical case review vendors.

Desired Qualifications

  • Working knowledge of applicable FDA, EU, and ICH guidelines, regulations, and initiatives governing safety reporting and processing, particularly in the clinical trial environment, is highly preferred.
  • Knowledge of or experience in medical review of medical devices and/or combination-product safety information is preferred.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs